Cargando…

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis

INTRODUCTION: The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polyzos, Konstantinos A., Mavros, Michael N., Vardakas, Konstantinos Z., Makris, Marinos C., Rafailidis, Petros I., Falagas, Matthew E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420911/ https://www.ncbi.nlm.nih.gov/pubmed/22916113 http://dx.doi.org/10.1371/journal.pone.0041870

Ejemplares similares

Understanding of Statistical Terms Routinely Used in Meta-Analyses: An International Survey among Researchers
por: Mavros, Michael N., et al.
Publicado: (2013)

Impact of Vacuum-Assisted Closure (VAC) Therapy on Clinical Outcomes of Patients with Sternal Wound Infections: A Meta-Analysis of Non-Randomized Studies
por: Falagas, Matthew E., et al.
Publicado: (2013)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?
por: Chuan, Junlan, et al.
Publicado: (2016)

Attributable mortality of Acinetobacter baumannii: no longer a controversial issue
por: Falagas, Matthew E, et al.
Publicado: (2007)

Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
por: Falagas, Matthew E., et al.
Publicado: (2014)

Do Psychological Variables Affect Early Surgical Recovery?
por: Mavros, Michael N., et al.
Publicado: (2011)

Temporal Trends (1999–2015) in the Impact Factor of Biomedical Journals Published by US and EU Scientific Societies
por: Falagas, Matthew E., et al.
Publicado: (2018)

Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review
por: Rafailidis, Petros I, et al.
Publicado: (2008)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
por: Rodriguez, George D, et al.
Publicado: (2017)

The effect of psychosocial factors on breast cancer outcome: a systematic review
por: Falagas, Matthew E, et al.
Publicado: (2007)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Worldwide Prevalence of Head Lice
por: Falagas, Matthew E., et al.
Publicado: (2008)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital
por: Falagas, Matthew E, et al.
Publicado: (2006)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
por: Bradley, John S., et al.
Publicado: (2023)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Trends of Mortality in Greece Prior to and During Its Current Financial Crisis (2009–2015)
por: Vardakas, Konstantinos Z., et al.
Publicado: (2019)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
por: Anastasilakis, Athanasios D, et al.
Publicado: (2012)

Serologic indices of hepatitis B virus infection in military recruits in Greece (2004–2005)
por: German, Vasilios, et al.
Publicado: (2006)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions
por: Gu, Zhengtian, et al.
Publicado: (2015)

Contrast-enhanced ultrasonography of the carotids
por: Rafailidis, Vasileios, et al.
Publicado: (2015)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lcp1cig2bpbuspthljqig4pu93